01.05.26 -- Survey: SUS Insufficient For 40% Of Biopharma

Learn about the defining criteria and varied tissue sources of MSCs. Discover their expanding role in therapies targeting inflammatory conditions and tissue regeneration.

Review the rapidly evolving world of complex drug development and the critical factors that drive success for products made using different molecules beyond the traditional antibodies.

Discover various strategies to enhance viral titer and increase the percentage of full AAV capsids, like modifications to transfection reagents, cell lines, media, procedures, and more.

New technologies for the encapsulation of nucleic acids, such as FDmiX, can potentially overcome limitations of currently available standard mixing technologies.

Explore the use of transposase/transposon systems in the biotech industry, particularly in the development of stable cell lines for protein manufacturing.

Scaling up life-saving gene-edited cell therapies means tackling production inefficiencies. Overcoming the time-consuming and risky cell washing step is crucial for clinical and commercial success.

See how stirred-tank bioreactors overcome the scalability limitations of static culture for MSC-EV production, while Raman spectroscopy provides unprecedented real-time quality monitoring.

Here, we describe the design and performance of a degenerate PCR-based approach to broad virus screening that can be used in testing bulk harvest material derived from CHO cells.